skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

もっと見る

Resources

もっと見る

もっと見る

Products

もっと見る

もっと見る

56 Total results for product and free and sample content found

Generics Bulletin: ジェネリック&バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic biosimilars deal-trends

Generics Bulletin: ジェネリック&バイオシミラーニュース

Celltrion's Remsima SC Ready For Early 2020 Launch

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

Topic Biosimilars Launches Regulation

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

The evolving landscape of biosimilars

The evolving landscape of biosimilars

It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.

Topic biosimilars

Generics Bulletin: ジェネリック&バイオシミラーニュース

Alberta Is Second Canadian Province To Switch To Biosimilars

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Topic biosimilars Regulation

Generics Bulletin: ジェネリック&バイオシミラーニュース

Pfizer Reports 80% Biosimilars Growth In Q3

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus biosimilars deal-trends

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Germany Sets Direction Of Travel With New Biosimilar Guidelines

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in move towards increasing biosimilar uptake.

Topic EU Biosimilars

Chemist + Druggist Data

UK Sees PIP Codes Expand To Cover Hospital Drugs

Pharmacists PIP Code Expansion

Chemist + Druggist has expanded its “PIP code” system for UK pharmacy procurement to also encompass hospital drugs.

Topic biopharmaceutical Regulation biosimilars

Generics Bulletin: ジェネリック&バイオシミラーニュース

Top 50 Generics and Biosimilars Companies

The Annual Top 50 Generics & Biosimilars Companies League Table is here, and Generics Bulletin is sharing its content with you! Connect to league tables and commentary summarizing key developments for the Top 10 companies in generics and biosimilars, part of Generics Bulletin’s annual Top 50 ranking.

Topic biosimilars

Generics Bulletin: ジェネリック&バイオシミラーニュース

Biosimilars Conference Coverage

Biosimilars Conference Coverage

Industry analysts from Generics Bulletin are bringing you free insights from their comprehensive biosimilars coverage. Obtain critical industry information covering new biosimilars launches, company strategies, and new biosimilars product development.

Topic biosimilars

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。